Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...

H.C. Wainwright analyst Andres Maldonado initiated coverage of ImmunityBio (IBRX) with a Buy rating and $8 price target ImmunityBio is a ...

Highlights,The New York State Common Retirement Fund raised its stake in ImmunityBio by 62.8% in the fourth quarter.,Several ...

We recently compiled a list of the Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a look at ...

The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the ...

Full Year 2024 Results Key Financial Results Revenue: US$14.7m (up by US$14.1m from ...

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) traded up 6.8% on Tuesday following a better than expected earnings announcement. The stock traded as high as $3.01 and last traded at $3.05.

Immunitybio Inc ( ($IBRX) ) has released its Q4 earnings. Here is a breakdown of the information Immunitybio Inc presented to its investors.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-c ...

Reports Q4 revenue $7.55M, consensus $9.51M. “The first quarter of 2025 has been an inflection point for the Company with multiple milestones ...

ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.19 per share a year ago. These figures are ...

ImmunityBio’s revenue growth was driven by sales of its ANKTIVA therapy following FDA approval in April 2024. The company reported net product revenue of $7.2 million for Q4, representing a 21% ...